Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
S-222611 是一种口服可逆酪氨酸激酶抑制剂,可抑制表皮生长因子受体和人表皮生长因子受体 2,其临床前抗肿瘤活性研究
期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.12449
Tanaka Hidekazu, Hirata Michinari, Shinonome Satomi, Wada Toru, Iguchi Motofumi, Dohi Keiji, Inoue Makiko, Ishioka Yukichi, Hojo Kanji, Yamada Tomomi, Sugimoto Tatsuya, Masuno Koichi, Nezasa Ken-Ichi, Sato Norihito, Matsuo Kenji, Yonezawa Shuji, Frenkel Eugene P, Shichijo Michitaka